Pioglitazone for heart failure with preserved pumping in type 2 diabetes
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial tests whether pioglitazone (a diabetes medicine) helps people who have type 2 diabetes and a specific type of heart failure where the heart pumps normally. It may improve heart failure symptoms and function in carefully selected patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign a consent form and can follow the study for its full duration
- You’re age 30 to 70 and your BMI is 27.5 to 40
- Your type 2 diabetes labs (HbA1c) are between 6.5 and 10
- Your kidney function is adequate (eGFR above 45), and your blood pressure is not over 145/65
- You have HFpEF (heart failure with preserved pumping, ejection fraction over 50%) and NYHA class II to III heart symptoms
- You are on an approved diabetes treatment (diet/exercise, metformin, sulfonylurea, metformin+SU, DPP-4 inhibitor, or insulin)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study looks at people with type 2 diabetes and certain types of heart failure to see whether changes in “ketones” relate to heart benefits. It may help researchers understand who could benefit most from treatment-related metabolism changes.
This trial tests whether incretin-based diabetes medications (like GLP-1 drugs) can help people with a specific type of heart failure called HFpEF that is linked to obesity. The goal is to see if these drugs improve heart function and symptoms.
This trial studies whether two medicines—an SGLT2 inhibitor and potassium nitrate—can improve symptoms and heart function in people with heart failure with preserved ejection fraction (HFpEF). It focuses on people who still have signs of “stiff” or high filling pressure in the heart despite a normal-ish ejection fraction.
This clinical trial looks at whether adding a special diet supplement (ketones) to an SGLT2 inhibitor diabetes drug improves heart function and symptoms in people who have both type 2 diabetes and heart failure with a weakened heart muscle.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This trial tests whether the diabetes drug glimepiride can help people who have both type 2 diabetes and heart failure (where the heart doesn't pump blood well). It aims to see if this medication improves heart function and overall health in this group.
Hear when a new Type 2 Diabetes Mellitus in Obese trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.